CCN2 and liver dysplastic nodule: Accordingly, in 2007, Guha et al. [49] published one of the first studies using an ASO-gapmer targeting connective tissue growth factor (Ctgf), an upregulated mediator of the TGFβ pathway that contributes to the pathology of DN.